|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0023449,
umls-concept:C0023467,
umls-concept:C0087111,
umls-concept:C0183683,
umls-concept:C0332161,
umls-concept:C0344211,
umls-concept:C1171411,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1317973,
umls-concept:C1515273,
umls-concept:C1521721,
umls-concept:C1521761,
umls-concept:C1705313,
umls-concept:C1948023,
umls-concept:C2348205
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1999-11-17
|
|
pubmed:abstractText |
Despite modern treatment programs, less than 20% of adult cases of acute lymphoblastic leukemia (ALL) are cured. For relapsing and/or refractory patients, use of high dose cytosine arabinoside (ara-C) and anthracyclin achieved a complete remission (CR) rate of up to a 75%. The aim of this study was to evaluate in adult patients with ALL 1) the CR rate of a chemotherapy schedule similar to a schedule for acute myeloblastic leukemia (AML) patients, 2) the antileukemic value and the tolerance of 3 intensive stage treatments, and 3) the impact of recombinant granulocyte-macrophage-colony stimulating factor (rGM-CSF) on chemotherapy-induced neutropenia and infectious complications, as well as the effect of dose intensity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BerthouCC,
pubmed-author:CahnJ YJY,
pubmed-author:FrançoisSS,
pubmed-author:GümzWW,
pubmed-author:GuyotatDD,
pubmed-author:HarousseauJ LJL,
pubmed-author:IfrahNN,
pubmed-author:JouetJ PJP,
pubmed-author:LinassierCC,
pubmed-author:PignonBB,
pubmed-author:WitzFF
|
|
pubmed:copyrightInfo |
Copyright 1999 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1496-505
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10526278-Adolescent,
pubmed-meshheading:10526278-Adult,
pubmed-meshheading:10526278-Bone Marrow Transplantation,
pubmed-meshheading:10526278-Combined Modality Therapy,
pubmed-meshheading:10526278-Female,
pubmed-meshheading:10526278-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:10526278-Humans,
pubmed-meshheading:10526278-Leukemia, Myeloid, Acute,
pubmed-meshheading:10526278-Male,
pubmed-meshheading:10526278-Middle Aged,
pubmed-meshheading:10526278-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:10526278-Recombinant Proteins,
pubmed-meshheading:10526278-Remission Induction,
pubmed-meshheading:10526278-Survival Analysis,
pubmed-meshheading:10526278-Survival Rate,
pubmed-meshheading:10526278-Time Factors,
pubmed-meshheading:10526278-Transplantation, Autologous,
pubmed-meshheading:10526278-Transplantation, Homologous,
pubmed-meshheading:10526278-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group.
|
|
pubmed:affiliation |
Service de Médecine D, CHU, Angers, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
